Granules India is currently trading at Rs. 131.45, up by 6.10 points or 4.87% from its previous closing of Rs. 125.35 on the BSE.
The scrip opened at Rs. 126.70 and has touched a high and low of Rs. 132.40 and Rs. 126.25 respectively. So far 216372 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 151.15 on 14-Jul-2016 and a 52 week low of Rs. 91.45 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 132.40 and Rs. 121.10 respectively. The current market cap of the company is Rs. 2903.50 crore.
The promoters holding in the company stood at 51.88%, while institutions and non-institutions held 7.24% and 40.88% respectively.
Granules India, one of the leading drug makers in India, is reportedly planning to invest $84 million in setting up new capacities, expanding existing ones and investing in R&D to improve its product mix in favour of higher value-added products. The project cost is proposed to be financed with debt of $68.5 million, including a corporate loan of up to $47.5 million from International Finance Corporation (IFC), and the rest through equity and internal accruals.
Granules India is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs).
